logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Biogen Inc. drugs

    FiltersReset Filters
    8 results

    • avonex

      (interferon beta-1a)
      Biogen Inc.
      Usage: AVONEX is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • byooviz

      (ranibizumab-nuna)
      BIOGEN INC.
      Usage: BYOOVIZ is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).

    • plegridy

      (peginterferon beta-1a)
      Biogen Inc.
      Usage: PLEGRIDY is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive MS.

    • qalsody

      (tofersen)
      Biogen Inc.
      Usage: QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a superoxide dismutase 1 (SOD1) gene mutation. Approval is based on reduced plasma neurofilament light chain (NfL) levels, with continued approval pending verification of clinical benefit from further trials.

    • tecfidera

      (dimethyl fumarate)
      Biogen Inc.
      Usage: TECFIDERA is indicated for treating relapsing forms of multiple sclerosis in adults, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • tofidence

      (TOCILIZUMAB)
      Biogen Inc.
      Usage: TOFIDENCE™ (tocilizumab-bavi) is indicated for treating moderately to severely active rheumatoid arthritis in adults who have not responded adequately to DMARDs, as well as active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.

    • tysabri

      (natalizumab)
      Biogen Inc.
      Usage: TYSABRI is indicated for the treatment of relapsing forms of multiple sclerosis in adults and for inducing and maintaining clinical response in adults with moderately to severely active Crohn's disease, who have not adequately responded to or cannot tolerate conventional therapies. Risks should be carefully considered.

    • vumerity

      (diroximel fumarate)
      Biogen Inc.
      Usage: VUMERITY is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.